Secord, Angeles A.
Coleman, Robert L.
Havrilesky, Laura J.
Abernethy, Amy P.
Samsa, Gregory P.
Cella, David
Article History
First Online: 10 March 2015
Competing interests
: A.A.S. has received research funding from Astellas Pharma, Astex Pharmaceuticals, Boerhinger Ingelheim, Bristol–Myers Squibb (BMS), Eisai-Morphotek, Genentech, Incyte, Precision Therapeutics, and Sanofi–Aventis. A.A.S. has served on Advisory Boards for Boerhinger Ingelheim, Genentech, GSK and Precision Therapeutics. R.L.C. has served on the Scientific Steering Committee for Amgen, Amo Therapeutics, Astellas Pharma Global Dev., BioMarin Pharmaceutical, Clovis Oncology, Eisai-Morphotek, Esperance Pharmaceuticals, Genentech, GSK, Janssen, Oxygene, Precision Therapeutics and Sanofi–Aventis. R.L.C. has served on an Independent Data Monitoring Committee for a trial sponsored by Johnson & Johnson, and has received research funding from Abbott Laboratories, Amgen, Array Bio, Clovis, EMD-Serono, Merck, Merrimack, Millennium, Novartis, Oncomed, and Sanofi-Aventis. A.P.A has received research funding from the Celgene; DARA; Dendreon; GSK; Helsinn; National Institute of Nursing Research, National Cancer Institute, Agency for Healthcare Research and Quality; and Pfizer. Since 2011 she has had nominal consulting agreements with or received honoraria from BMS, Novartis and Pfizer. Further consulting with BMS is pending in 2014, for a role as Co-Chair of a Scientific Advisory Committee. A.P.A. has a paid leadership role with American Academy of Hospice & Palliative Medicine (President) and has corporate leadership responsibility in Advoset (an education company), athenahealth (health information technology (IT) company), and Orange Leaf Associates (an IT development company). D.C. has received research funding from GlaxoSmithKline (GSK) and Pfizer. He has also served as a consultant for Clovis Oncology, Genentech and GSK. L.J.H. and G.P.S. declare no competing interests.